top of page

ASGCT 2026: Epicrispr Biotechnologies is already in the clinic with its epigenetic approach to genetic medicine. At ASGCT, it showed off how versatile this platform might be

May 12

1 min read

CEO Amber Salzman walks us through the science, which allows the company to dial up or dial down genes of interest rather than making a cut into the DNA. They have dosed patients with FSHD, a type of muscular dystrophy, and have ASGCT presentations looking at other indications like Friedreich's ataxia, a type of Alzheimer's, and DMD.

https://vimeo.com/1191657872?share=copy&fl=sv&fe=ci

Coverage brought to you by

Recent Posts

See All

Formation Bio announced a $600M fund it will use to acquire 10–15 drug programs over the next 3–5 years - it is a step in its plan to make drug development more efficient and become 'the next pharma'

Zentalis aims to deliver to the ovarian cancer community a precision medicine approach - a targeted (WEE1) oral therapy for patients who are Cyclin E1 positive

BIO-Europe 2026: Bionyra Pharma emerged from stealth earlier this year with $165m in series A financing and three in-licensed assets: a TL1A Mab, a TL1A*IL-23p19 bispecific, and an IL-25 Mab

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

Mispro is an AAALAC-accredited contract vivarium organization (CVO) offering a network of full-service vivarium rental lab facilities for preclinical in vivo rodent studies. Along with access to state-of-the-art lab spaces, Mispro supports its clients with comprehensive laboratory animal research services, including husbandry, veterinary, technical, and regulatory compliance oversight. With locations in all major U.S. biotech hubs, Mispro is committed to helping biosciences companies of all sizes and therapeutic indications achieve their research goals.

Learn more